Evaluating prescribing practices of apixaban in the elderly
E Pogge, S Sibicky, A Campbell - The Senior Care Pharmacist, 2019 - ingentaconnect.com
OBJECTIVE: The aim of this study was to evaluate prescribing practices for elderly patients
started on apixaban in multiple practice settings. DESIGN: Retrospective, chart review …
started on apixaban in multiple practice settings. DESIGN: Retrospective, chart review …
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients≥ 75 and< …
S Deitelzweig, A Amin, Y Jing… - Journal of Medical …, 2013 - Taylor & Francis
Objectives: Based on clinical trials the oral anticoagulants (OACs) apixaban, dabigatran,
and rivaroxaban are efficacious for reducing stroke risk for non-valvular atrial fibrillation …
and rivaroxaban are efficacious for reducing stroke risk for non-valvular atrial fibrillation …
Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population …
Background: Current guidelines recommend using direct oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …
[HTML][HTML] Cost-Effectiveness of apixaban compared with edoxaban for stroke prevention in nonvalvular atrial fibrillation
GYH Lip, T Lanitis, T Kongnakorn, H Phatak… - Clinical Therapeutics, 2015 - Elsevier
Purpose The purpose of this analysis was to assess the cost-effectiveness of apixaban 5 mg
BID versus high-and low-dose edoxaban (60 mg and 30 mg once daily) as intended starting …
BID versus high-and low-dose edoxaban (60 mg and 30 mg once daily) as intended starting …
A Comparison of Bleeding Events Among Patients on Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism
JK Schaefer, J Errickson, X Kong, MA Ali, N Chipalkatti… - Blood, 2023 - Elsevier
Introduction Apixaban and rivaroxaban are the most commonly used direct oral
anticoagulants (DOACs) for atrial fibrillation (AF) and venous thromboembolism (VTE). Both …
anticoagulants (DOACs) for atrial fibrillation (AF) and venous thromboembolism (VTE). Both …
Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials?—a systematic review
TAC de Vries, J Hirsh, K Xu, I Mallick… - Thrombosis and …, 2020 - thieme-connect.com
Background Recent reports suggest an important contribution from frequent off-label use of
apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in …
apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in …
Effectiveness and safety of apixaban, dabigatran, and rivaroxaban compared to warfarin among non-valvular atrial fibrillation patients in the us medicare population
A Amin, A Keshishian, J Trocio, H Le, O Dina… - Journal of the American …, 2017 - jacc.org
Background: Clinical trials have shown direct oral anticoagulants (DOACs) are at least as
effective and safe as warfarin for risk of stroke/systemic embolism (S/SE) and major bleeding …
effective and safe as warfarin for risk of stroke/systemic embolism (S/SE) and major bleeding …
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation
S Halvorsen, L Wallentin, H Yang, RD Caterina… - Journal of the American …, 2013 - jacc.org
Background The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the
ARISTOTLE trial, apixaban as compared with warfarin reduced the rate of stroke, death and …
ARISTOTLE trial, apixaban as compared with warfarin reduced the rate of stroke, death and …
Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants
AM Gilligan, J Franchino-Elder, X Song… - … medical research and …, 2018 - Taylor & Francis
Objectives: Compare costs and healthcare resource utilization (HCRU) among newly-
diagnosed non-valvular atrial fibrillation (NVAF) patients newly treated with dabigatran vs …
diagnosed non-valvular atrial fibrillation (NVAF) patients newly treated with dabigatran vs …
Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry
S Helmert, S Marten, H Mizera, A Reitter… - Journal of Thrombosis …, 2017 - Springer
The effectiveness and safety of apixaban for stroke prevention in atrial fibrillation (SPAF)
demonstrated in ARISTOTLE needs to be confirmed in daily care. To evaluate effectiveness …
demonstrated in ARISTOTLE needs to be confirmed in daily care. To evaluate effectiveness …